
|Articles|October 13, 2022
The Daily Dose: IBS Phenotypes
Author(s)Sydney Jennings
Your daily dose of clinical news from Patient Care Online.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study.
The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 12, 2022, we reviewed a study published in Clinical Gastroenterology and Hepatology, that highlights the importance of expanding clinical profiles of irritable bowel syndrome beyond GI symptoms based on predominant bowel habits.
The study
Researchers identified 4021 IBS patients and 12 063 non-IBS control patients. Using 26 variables to distinguish IBS cases from control cases, the resulting optimal clustering revealed 7 latent clusters. According to the study, 2 clusters had moderate-to-severe perceived impairment in health, greater pain but less bowel dysfunction and 3 were predominated by neurological, psychological, or neuropsychological complaints. The last 2 had greater bowel dysfunction (diarrhea or constipation predominance) but less pain, perceived health impairment, and other comorbidities.
Clinical implications
"IBS phenotype has multiple dimensions that may be driven by unique pathophysiology, resulting in variable clinical course. Clinical trials and personalized treatment approaches may benefit from going beyond the current concepts of predominant bowel patterns and targeting specific clusters of IBS patients," wrote investigators.
Click here for the full study review.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
7 Drugs Approved for Primary Care: Q3 2025
2
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial
3
FAQs On The Critical Window Hypothesis for Menopausal Hormone Therapy's Neuroprotective Effects
4
Why Do Women Suffer in Silence with Genitourinary Syndrome of Menopause?
5










































































































































































































































































































